Phase I Sudy Combining Gefitinib With Docetaxel And Estramustine Reported

... UroToday.com - Combination docetaxel regimens have been shown to improve overall survival in randomized clinical trial in patients with hormone-refractory prostate cancer (CaP). Gefitinib is an oral epidermal growth factor receptor inhibitor (EGFR). It is active against CaP cell lines and xenografts. Given alone, gefitinib was not highly active in hormone-refractory CaP patients. Dr. [click link for full article] ...